Breaking News

Tweet TWEET

Jazz Pharmaceuticals Announces Participation At Two Investor Conferences In March

 Jazz Pharmaceuticals Announces Participation At Two Investor Conferences In
                                    March

  PR Newswire

  DUBLIN, Feb. 27, 2013

DUBLIN, Feb. 27, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ)
announced today that the company will participate in two upcoming investor
conferences. A live webcast of each presentation may be accessed from the
Investors section of the Jazz Pharmaceuticals website at
www.jazzpharmaceuticals.com . The conferences, presentation times and speakers
include:

  *Cowen and Company 33rd Annual Healthcare Conference in Boston, MA on
    Wednesday, March 6, 2013 at 8:40 a.m. EST/1:40 p.m. GMT. Kathryn Falberg,
    executive vice president and chief financial officer, will provide a
    business update.
  *Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 12,
    2013 at 9:00 a.m. EST/2:00 p.m. GMT. Bruce Cozadd, chairman and chief
    executive officer, will provide a business update.

An archived version of each webcast will be available for at least one week
following each respective presentation on the Investors section of the
company's website at www.jazzpharmaceuticals.com .

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on
improving patients' lives by identifying, developing and commercializing
innovative products that address unmet medical needs. The company has a
diverse portfolio of products in the areas of narcolepsy, oncology, pain and
psychiatry. The company's U.S. marketed products in these areas include:
Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia
chrysanthemi ), Prialt® (ziconotide) intrathecal infusion, Luvox CR®
(fluvoxamine maleate), FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of
the U.S., Jazz Pharmaceuticals also has a number of products marketed by its
EUSA Pharma division. For further information, see www.jazzpharmaceuticals.com
.

Website: http://www.jazzpharmaceuticals.com
Contact: For Investors, Kathee Littrell, Vice President, Investor Relations,
Jazz Pharmaceuticals plc, Ireland, + 353 1 634 7887, U.S., +1-650-496-2717,
For Media, Ami Knoefler, Executive Director, Corporate Communications, Jazz
Pharmaceuticals plc, Ireland, + 353 1 638 1032, U.S., +1-650-496-2947
 
Press spacebar to pause and continue. Press esc to stop.